Form 4: SOLENO CDO Granted Equity Awards Under 10b5-1 Plan

Soleno Therapeutics' Chief Development Officer, Manher Joshi, was granted 16,071 restricted stock units and options to purchase 72,321 shares of common stock.

Summary

• Manher Joshi, Chief Development Officer of Soleno Therapeutics Inc. (SLNO), was granted equity awards on November 10, 2025.
• The awards include 16,071 restricted stock units (RSUs) and options to acquire 72,321 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.
• Each RSU represents a contingent right to receive one share of Common Stock, with a grant price of $0.
• The stock options have an exercise price of $46.31 per share and a grant price of $0.
• Following these transactions, Manher Joshi beneficially owns 16,071 RSUs and 72,321 stock options directly.

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive is generally a positive for executive retention and aligning management interests with shareholders. It does not, however, provide direct insight into operational or financial performance, hence a moderately positive score.

Positives

• The grant of equity awards aligns the Chief Development Officer's interests with those of shareholders, promoting long-term value creation.
• Equity compensation serves as a retention tool for key executives, ensuring continuity in leadership and strategic development.
• The use of a Rule 10b5-1 plan demonstrates a structured and pre-planned approach to executive compensation.

Negatives

• The future vesting and exercise of these awards will result in dilution for existing shareholders as new shares are issued.

Risks

• Vesting of both RSUs and stock options is contingent upon the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2014 Equity Incentive Plan) through each vesting date.

Future Outlook

The equity grants are designed to provide long-term incentives and align the Chief Development Officer's future performance with the company's strategic goals and shareholder value creation, subject to continued service and vesting schedules.

Industry Context

The grant of equity awards to a Chief Development Officer is a standard practice in the biotechnology and pharmaceutical industry, used to attract, retain, and motivate key talent responsible for product development and pipeline advancement. This compensation structure is common for companies at various stages of development.

Comparison to Industry Standards

• The structure of these equity grants, including RSUs and stock options with multi-year vesting schedules, is consistent with typical executive compensation packages observed in the biotech sector.
• The use of a Rule 10b5-1 plan is a common corporate governance practice for executives to manage their stock transactions in compliance with insider trading rules.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units and stock options to Manher Joshi, the Chief Development Officer, constitutes a related party transaction as it involves compensation to an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards, but also benefit from aligned executive incentives.
• Employees: Reflects standard executive compensation practices, potentially influencing broader compensation strategies within the company.

Next Steps

• One-half of the RSUs will vest on November 10, 2026, with one-third of the remaining RSUs vesting each one-year anniversary thereafter.
• One-fourth of the shares subject to the option will vest on November 10, 2026, with one forty-eighth of the shares vesting each month thereafter.
• Continued service of the Chief Development Officer is required for vesting of both RSUs and stock options.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a key executive, which is a positive for management retention and alignment of interests with shareholders. However, it does not contain information about the company's operational or financial performance that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the fundamental investment thesis.

Keywords

Soleno Therapeutics, SLNO, Form 4, Restricted Stock Units, RSU, Stock Options, Equity Grant, Executive Compensation, Manher Joshi, Chief Development Officer, 10b5-1 Plan